Hospital Resource Utilization and Costs of Inappropriate Treatment of Candidemia

被引:78
作者
Arnold, Heather M. [7 ]
Micek, Scott T. [7 ]
Shorr, Andrew F. [5 ,6 ]
Zilberberg, Marya D. [3 ,4 ]
Labelle, Andrew J. [1 ]
Kothari, Smita [2 ]
Kollef, Marin H. [1 ]
机构
[1] Washington Univ, Sch Med, Div Pulm & Crit Care, St Louis, MO 63110 USA
[2] Astellas Pharma US Inc, Deerfield, IL USA
[3] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA
[4] EviMed Res Grp LLC, Goshen, MA USA
[5] Georgetown Univ, Washington, DC USA
[6] Washington Hosp Ctr, Pulm & Crit Care Med Serv, Washington, DC 20010 USA
[7] Barnes Jewish Hosp, Dept Pharm, St Louis, MO 63110 USA
来源
PHARMACOTHERAPY | 2010年 / 30卷 / 04期
关键词
candidemia; fluconazole; echinocandin; resource utilization; RISK-FACTORS; INVASIVE CANDIDIASIS; FLUCONAZOLE THERAPY; UNITED-STATES; MORTALITY; EPIDEMIOLOGY; ALBICANS; OUTCOMES;
D O I
10.1592/phco.30.4.361
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objectives. To evaluate the impact of inappropriate therapy-defined as delayed antifungal therapy beyond 24 hours from culture collection, inadequate antifungal dosage, or administration of an antifungal to which an isolate was considered resistant-on postculture hospital length of stay and costs, and to evaluate the relationship between modifiable risk factors, including failure to remove a central venous catheter, antifungal delay, and inadequate dosage, for an additive effect on hospital length of stay and costs. Design. Single-center retrospective cohort study. Setting. 1250-bed academic medical center. Patients. One hundred sixty-seven consecutive adult patients admitted between January 2004 and May 2006 with culture-confirmed Candida bloodstream infections that occurred within 14 days of hospital admission and who received at least one dose of antifungal treatment. Measurements and Main Results. Patients were stratified according to appropriateness of antifungal therapy. Appropriate therapy was defined as initiation of an antifungal to which the isolated pathogen was sensitive in vitro within 24 hours of positive culture collection, in addition to receipt of an adequate close as recommended by the Infectious Diseases Society of America and the antifungal package insert. Postculture length of stay was the primary outcome and hospital costs the secondary outcome. An evaluation of modifiable risk factors was performed separately. Data were analyzed for 167 patients (22 in the appropriate therapy group and 145 in the inappropriate therapy group). Postculture length of stay was shorter in the appropriate therapy group (mean 7 vs 10.4 days, p=0.037). This correlated with total hospital costs that were lower in the appropriate therapy group (mean $15,832 vs $33,021, p<0.001.) A graded increase in costs was noted with increasing number of modifiable risk factors (p=0.001). Conclusion. Inappropriate therapy for Candida bloodstream infection occurring within 14 days of hospitalization was associated with prolonged postculture length of stay and increased costs. A rise in costs, but not length of stay, was noted with increasing modifiable risk factors.
引用
收藏
页码:361 / 368
页数:8
相关论文
共 20 条
  • [1] Risk factors for albicans and non-albicans candidemia in the intensive care unit
    Chow, Jennifer K.
    Golan, Yoav
    Ruthazer, Robin
    Karchmer, Adolf W.
    Carmeli, Yehuda
    Lichtenberg, Deborah A.
    Chawla, Varun
    Young, Janet A.
    Hadley, Susan
    [J]. CRITICAL CARE MEDICINE, 2008, 36 (07) : 1993 - 1998
  • [2] Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study
    Garey, Kevin W.
    Turpin, Robin S.
    Bearden, David T.
    Pai, Manjunath P.
    Suda, Katie J.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (05) : 557 - 562
  • [3] Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study
    Garey, Kevin W.
    Rege, Milind
    Pai, Manjunath P.
    Mingo, Dana E.
    Suda, Katie J.
    Turpin, Robin S.
    Bearden, David T.
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) : 25 - 31
  • [4] Treatment-related risk factors for hospital mortality in Candida bloodstream infections
    Labelle, Andrew J.
    Micek, Scott T.
    Roubinian, Nareg
    Kollef, Marin H.
    [J]. CRITICAL CARE MEDICINE, 2008, 36 (11) : 2967 - 2972
  • [5] Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance
    Morgan, J
    Meltzer, MI
    Plikaytis, BD
    Sofair, AN
    Huie-White, S
    Wilcox, S
    Harrison, LH
    Seaberg, EC
    Hajjeh, RA
    Teutsch, SM
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2005, 26 (06) : 540 - 547
  • [6] Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality
    Morrell, M
    Fraser, VJ
    Kollef, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) : 3640 - 3645
  • [7] Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
    Pappas, Peter G.
    Kauffman, Carol A.
    Andes, David
    Benjamin, Daniel K., Jr.
    Calandra, Thierry F.
    Edwards, John E., Jr.
    Filler, Scott G.
    Fisher, John F.
    Kullberg, Bart-Jan
    Ostrosky-Zeichner, Luis
    Reboli, Annette C.
    Rex, John H.
    Walsh, Thomas J.
    Sobel, Jack D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 48 (05) : 503 - 535
  • [8] Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005:: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing
    Pfaller, M. A.
    Diekema, D. J.
    Gibbs, D. L.
    Newell, V. A.
    Meis, J. F.
    Gould, I. M.
    Fu, W.
    Colombo, A. L.
    Rodriguez-Noriega, E.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (06) : 1735 - 1745
  • [9] Epidemiology of invasive candidiasis: a persistent public health problem
    Pfaller, M. A.
    Diekema, D. J.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2007, 20 (01) : 133 - +
  • [10] Candidemia in nonneutropenic critically ill patients:: Risk factors for non-albicans Candida spp.
    Playford, E. Geoffrey
    Marriott, Deborah
    Nguyen, Quoc
    Chen, Sharon
    Ellis, David
    Slavin, Monica
    Sorrell, Tania C.
    [J]. CRITICAL CARE MEDICINE, 2008, 36 (07) : 2034 - 2039